News Immunocore announces the presentation of initial data from the Phase 1 ImmTAV® trial for chronic Hepatitis B at the EASL International Liver Congress™ Continue Reading Previous Aleafia Health to Announce Fiscal Year 2022 Fifth Quarter and Year End Results – UpdateNext Arbutus Presents New Data on AB-729, AB-836 and AB-101 at the EASL International Liver Congress™ 2022 and Provides AB-836 Clinical Update Related Stories News Quickbase Announces New AI Tools to Empower Deskless Workforce; Customers Cut Accidents by 39% and Scale Revenue 500% News Pacific AI Becomes a Certified Assurance Resource Provider with the Coalition for Health AI (CHAI) News Coder Launches Blink: The Fastest Way to Build and Deploy AI Agents News QuarkXPress 2026 Delivers Advanced Mathematical Publishing Power for Academic & Technical Designing, and Improves Layout Precision News Rebuy Monetize Powered by Fluent Accelerates Merchant Growth as Partnership Scales Across Shopify News Métrica Móvil Integrates Geotab Ace™ into Its IRIS Fleet™ Platform, Revolutionizing Fleet Management in Mexico with Artificial Intelligence
